Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2020-06-04 Capital/Financing Update
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Results of Placing of Ordinary Shares
Capital/Financing Update Classification · 98% confidence The document begins with an 'RNS Number' and is dated June 4, 2020. The content explicitly announces the 'successful completion of the placing of new ordinary shares' (a capital raising event) and details the gross proceeds (£133.4 million), the number of shares placed, and the admission process to the London Stock Exchange. It also discusses total voting rights following the issuance. This clearly describes a financing activity involving the issuance of new capital, which aligns with the 'Capital/Financing Update' definition. Although it is a regulatory announcement (RNS format), the core subject matter is the capital raise, making 'CAP' the most specific classification over the general 'RNS' fallback. The document length is substantial (over 22k characters), indicating it is the primary announcement, not just a brief notice of publication.
2020-06-04 English
Proposed Placing of Ordinary Shares
Capital/Financing Update Classification · 98% confidence The document is an official announcement released via the RNS (Regulatory News Service) number 8796O by Dechra Pharmaceuticals PLC on June 3, 2020. The content explicitly details the 'Proposed Placing of Ordinary Shares' using an 'accelerated bookbuilding process' to raise capital. This action falls directly under the definition of a company fundraising or capital structure change activity. While it is an RNS announcement, the specific subject matter—a share placing/fundraising—is best classified under 'Capital/Financing Update' (CAP) rather than the general 'Regulatory Filings' (RNS) fallback, as CAP is a more specific category for this type of corporate action. The document is an announcement of the action, not a full report, but the action itself is capital raising.
2020-06-03 English
Trading Update
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and explicitly states it is released via RNS (National Storage Mechanism). It provides an unaudited Trading Update covering a specific period (1 July 2019 to 30 April 2020) and discusses financial highlights, operational reviews, and outlook, which aligns with an Earnings Release (ER) or an Interim Report (IR). However, the text also mentions: "Separately today, the Group is announcing a proposed placing (Placing)." This suggests the primary purpose of this specific RNS filing is to disseminate material, time-sensitive information, including trading updates and capital activity context, rather than being the comprehensive quarterly report itself (IR) or the formal earnings release (ER). Since it contains a trading update, financial highlights, and mentions a separate capital activity (Placing), it functions as a significant regulatory announcement. Given the context of providing key financial updates outside of a standard quarterly filing cycle (it covers a period ending April 30th, but the company's FY ends June 30th), and its format as an RNS announcement, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were the primary results announcement. Since it is explicitly an RNS announcement containing a Trading Update and mentioning a separate Placing announcement, RNS is the most accurate general classification for this type of market communication, although ER is a close second if the trading update is considered the core result disclosure. Given the explicit RNS header and the nature of disseminating material, non-standard report information, RNS is chosen as the most appropriate fallback/general regulatory announcement category.
2020-06-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly starts with 'RNS Number : 3749O' and mentions 'National Storage Mechanism'. It details the 'Total Voting Rights' (102,878,460 shares) as required by DTR 5.6.1R, which is a standard regulatory disclosure. While this information relates to share capital, the primary function of this specific filing is a mandatory regulatory notification disseminated via the RNS system, rather than a formal share issue announcement (SHA) or a transaction in own shares (POS). Since it is a general regulatory announcement provided through the RNS service, and it doesn't fit perfectly into the other specific categories like DVA (which is for voting *results*), RNS is the most appropriate general regulatory filing code.
2020-05-29 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content focuses on notifying the market about the 'Total Voting Rights' (102,876,460 ordinary shares) as of the announcement date, referencing DTR 5.6.1R. This type of mandatory, short-form regulatory disclosure, which is not a comprehensive report (like 10-K or IR) but a specific market update, fits best under the general 'Regulatory Filings' category (RNS) as it is a standard regulatory notification disseminated via the RNS system.
2020-04-30 English
Completion of Acquisition
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 16, 2020. It announces the 'Completion of Acquisition' of the Mirataz® product portfolio. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement of a material event provided via the RNS system—indicates a general regulatory disclosure. Since the content is a specific corporate action (acquisition completion) that doesn't fit perfectly into categories like ER, 10-K, or CAP (which is for fundraising/financing structure changes), the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as the fallback for miscellaneous regulatory announcements.
2020-04-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.